Thiamine

Treatment of thiamine deficiency/beriberi, including dry neurologic and wet cardiovascular presentations; rapid restoration in Wernicke encephalopathy, infantile collapse, deficiency-related cardiac disease or severe pregnancy neuritis/vomiting. Also indicated when established deficiency prevents adequate oral use, and with IV dextrose in marginal status to avoid precipitating heart failure. Isolated thiamine injection is not usually indicated for general poor intake/malabsorption, where multiple deficiencies need review.

ASAM recommends thiamine to prevent Wernicke encephalopathy during alcohol withdrawal. Suspected established disease requires a separate hospital regimen. Oral vitamin B1 supplements provide nutrition and are not FDA-preapproved drugs for safety/effectiveness; the selected injection is a current FDA Prescription product. This profile excludes veterinary products, benfotiamine substitution and unverified multivitamin emergency regimens.

Beriberi: 10–20 mg IM three times daily for up to 2 weeks, then an oral therapeutic multivitamin containing 5–10 mg thiamine daily for 1 month. Wet beriberi with myocardial failure is an emergency requiring slow IV treatment. Infantile collapse: label permits cautiously giving 25 mg IV; this is not a complete age-based pediatric algorithm. Pregnancy neuritis with severe vomiting: 5–10 mg IM daily. For marginal status with dextrose, the PI describes 100 mg in each of the first few liters of IV fluid. These instructions require professional assessment and monitored administration.

The current Avet PI retains historical Wernicke-Korsakoff directions: 100 mg IV initially, then 50–100 mg IM daily until a balanced diet. Current DHSC adult hospital guidance for suspected/established Wernicke instead recommends 300–500 mg IV three times daily for 3–5 days with daily review; if still symptomatic after 5 days, 300–500 mg IV once daily for a further 3–5 days and while improvement continues, followed by oral thiamine. Check/correct magnesium and investigate other causes of confusion. This guideline regimen differs from U.S. PI dosing and requires an appropriate local preparation/infusion protocol; neither a universal bolus rate nor dilution recipe is invented. The PI’s old claim that > 30 mg three times daily is not efficiently used is not a modern emergency-treatment ceiling.

ASAM: typical ambulatory oral dose 100 mg daily for 3–5 days; inpatient prevention typically 100 mg IV/IM daily for 3–5 days, favoring parenteral delivery with malnutrition, malabsorption or severe withdrawal complications. Glucose and thiamine can be given in either order or concurrently; do not delay urgent glucose. Current DHSC high-risk adult hospital prophylaxis is 200–300 mg IM/IV daily for 3–5 days with daily review and subsequent oral treatment. These are distinct prevention recommendations; new Wernicke signs require the full treatment pathway.

Daily RDA/AI in mg: birth–6 months 0.2 AI; 7–12 months 0.3 AI; ages 1–3: 0.5, 4–8: 0.6, 9–13: 0.9; ages 14–18 male 1.2/female 1.0; adults male 1.2/female 1.1; pregnancy/lactation 1.4. These are nutrition totals, not deficiency or emergency doses. Selected injection is IM or slow IV; inspect solution and seal before use. The PI supplies no numeric IV speed or fixed renal/hepatic adjustment, so consult the exact product and institutional preparation directions.

History of sensitivity to thiamine or any selected injection ingredient. Excipients matter: Avet contains chlorobutanol and monothioglycerol. Other brands may differ; vitamin status does not waive ingredient allergy.

Selected current Avet PI has no boxed warning. Its prominent aluminum warning and potentially fatal parenteral anaphylaxis remain important labeled risks; do not describe all vitamin products as uniformly harmless.

Reported effects include warmth, itching/urticaria, sweating, nausea, weakness, restlessness, throat tightness, angioedema, cyanosis, pulmonary edema and severe anaphylaxis/collapse; IM tenderness/induration can occur. Incidence is not established. Overdose or an administration error requires medical assessment; historical reports of tolerating large doses do not guarantee safety or eliminate hypersensitivity.

NIH identifies furosemide-associated urinary thiamine loss and fluorouracil-associated deficiency reports; assess nutrition rather than prescribe an automatic interaction correction. The selected PI has no comprehensive CYP interaction table. During withdrawal, ASAM permits thiamine and glucose in either order or concurrently; magnesium replacement is indicated with hypomagnesemia and other specified clinical risks. For injection admixtures, verify compatibility in the institutional protocol rather than infer it from oral-vitamin use.

The PI describes pregnancy use when clearly needed and a specific severe-vomiting neuritis regimen; its legacy pregnancy letter category is not a modern quantitative safety guarantee. The label states milk-excretion information is unknown and advises caution. Assess deficiency, maternal need and infant exposure rather than applying nutrient requirements as a disease-treatment ceiling.

The label describes infantile beriberi/collapse but does not provide a comprehensive pediatric dose table or age-specific Wernicke regimen. Adults’ withdrawal/emergency guidelines are not pediatric prescriptions. Premature infants have heightened aluminum accumulation risk; older adults require review of nutrition, organ function and allergy history rather than a fixed age dose.

No labeled numeric dose-adjustment algorithm. Renal impairment raises concern for parenteral aluminum accumulation; review cumulative sources and exposure duration. Hepatic disease can coexist with severe nutritional deficiency and alcohol-related risk, requiring clinical replacement assessment rather than unverified dose reduction.

Thiamine combines with ATP to form active thiamine pyrophosphate, involved in carbohydrate metabolism. IM absorption is described as rapid and complete; thiamine distributes widely, with high tissue concentrations in liver, brain, kidneys and heart. Excess is excreted through the kidneys. The selected PI supplies no validated numeric terminal half-life, protein-binding value or oral-to-parenteral conversion; no such estimate is invented.

Assess confusion, eye movements, gait, cardiac failure and intake/malabsorption; urgent suspected Wernicke treatment should not await an unneeded routine lab panel. During hospital treatment review response daily, electrolytes/magnesium and alternate causes of persistent symptoms. Watch injection hypersensitivity and site effects; assess renal function/cumulative aluminum with prolonged parenteral exposure. Arrange continued oral nutrition and follow-up.

Maintain a balanced diet and follow the prescribed replacement course to reduce relapse. Oral tablets are not an emergency substitute for confusion, eye-movement abnormalities or marked unsteadiness. Injection-related throat swelling, breathing difficulty or collapse requires immediate care. Review other vitamin products and medicines with the team; do not self-inject or use veterinary preparations.

Avet thiamine hydrochloride injection 100 mg/mL; 2 mL multidose vial contains 200 mg, NDC23155-933-31. Contains chlorobutanol 0.5% and monothioglycerol 0.5%; approved for IM or slow IV administration. The vial total is not a universal patient dose.

Selected Avet injectable is 100 mg/mL in 2 mL vials, current ANDA217181 Prescription. Oral supplements commonly use thiamine hydrochloride or mononitrate with product-specific strengths/servings; no claim that every oral supplement has FDA drug approval. Benfotiamine and combination multivitamin injections are outside executable dosing scope.

Store selected injection at 20–25°C and protect from light. Use only clear solution with intact seal; inspect for particles/discoloration. Use aseptic multidose handling under institutional standards; the PI does not establish an exact post-puncture discard interval, so do not invent one. Oral products follow their own packaging/storage instructions.